Form D · Biotechnology

Calimmune, Inc.

Tucson, AZ · CIK 0001643405

Offering snapshot reported May 28, 2015 · SEC filing

Reported sold
$15.9M
Offering amount: $16M
Investors reported
51
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 12, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 28, 2015Initial$15,851,969No comparison51SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-240650
The amount listed above includes the amount receivable upon the exercise of warrants to purchase shares of Common and Series B Preferred Stock. Such warrants have not yet been exercised.
Securities offered consist of Series B Pref Stock, Warrants exercisable for shares of Common and Series B Pref Stock, the Common and Series B Pref Stock issuable upon exercise of the Warrants and the common stock underlying the Series B Pref Stock.

Source: Form D, filed May 28, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Baltimore, Ph.D. Director
Louis Breton Director, Executive
David H. Donabedian, Ph.D. Director
Harry A. George Director
Jon Faiz Kayyem, Ph.D. Director
Peter Kolchinsky Director
Bhavin Raval Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5151 E. Broadway Blvd., Suite 1020
Tucson, AZ, 85711